Disease variants in genomes of 44 centenarians

Molecular Genetics and Genomic Medicine

Volumn 2, Issue 5, 2014, Pages 438-450

  Freudenberg Hua, Yun ^a,b   Freudenberg, Jan ^a   Vacic, Vladimir ^c   Abhyankar, Avinash ^c   Emde, Anne Katrin ^c   Ben Avraham, Danny ^d   Barzilai, Nir ^d   Oschwald, Dayna ^c   Christen, Erika ^a   Koppel, Jeremy ^a,b   Greenwald, Blaine ^b   Darnell, Robert B ^c,e   Germer, Soren ^c   Atzmon, Gil ^d   Davies, Peter ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c NEW YORK GENOME CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Aging; Ashkenazi; Centenarian; Disease gene; Incidental finding; Whole genome sequencing

Indexed keywords

EID: 84923375098     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.86     Document Type: Article

References (66)

1. Abbott, G. W., F. Sesti, I. Splawski, M. E. Buck, M. H. Lehmann, K. W. Timothy, et al. 1999. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175–187.
2. Andersen, P. S., O. Havndrup, H. Bundgaard, J. C. Moolman-Smook, L. A. Larsen, J. Mogensen, et al. 2001. Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations. J. Med. Genet. 38:E43.
3. Antzelevitch, C., G. D. Pollevick, J. M. Cordeiro, O. Casis, M. C. Sanguinetti, Y. Aizawa, et al. 2007. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115:442–449.
4. Barzilai, N., G. Atzmon, C. Schechter, E. J. Schaefer, A. L. Cupples, R. Lipton, et al. 2003. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290:2030–2040.
5. Beekman, M., H. Blanche, M. Perola, A. Hervonen, V. Bezrukov, E. Sikora, et al. 2013. Genome-wide linkage analysis for human longevity: genetics of Healthy Aging Study. Aging Cell 12:184–193.
6. Bergman, A., G. Atzmon, K. Ye, T. MacCarthy, and N. Barzilai. 2007. Buffering mechanisms in aging: a systems approach toward uncovering the genetic component of aging. PLoS Comput. Biol. 3:e170.
7. Berndt, I., M. Reuter, B. Saller, K. Frank-Raue, P. Groth, M. Grussendorf, et al. 1998. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J. Clin. Endocrinol. Metab. 83:770–774.
8. Bertina, R. M., B. P. Koeleman, T. Koster, F. R. Rosendaal, R. J. Dirven, H. de Ronde, et al. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67.
9. Bravo, G., and R. Hebert. 1997. Age-and education-specific reference values for the Mini-Mental and modified Mini-Mental State Examinations derived from a non-demented elderly population. Int. J. Geriatr. Psychiatry 12:1008–1018.
10. Camp, N. J., and S. V. Tavtigian. 2002. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am. J. Hum. Genet. 71:1475–1478.
11. Casas, J. P., A. D. Hingorani, L. E. Bautista, and P. Sharma. 2004. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch. Neurol. 61:1652–1661.
12. Cassa, C. A., M. Y. Tong, and D. M. Jordan. 2013. Large numbers of genetic variants considered to be pathogenic are common in asymptomatic individuals. Hum. Mutat. 34:1216–1220.
13. Cooper, D. N., M. Krawczak, C. Polychronakos, C. Tyler-Smith, and H. Kehrer-Sawatzki. 2013. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum. Genet. 132:1077–1130.
14. Corydon, M. J., J. Vockley, P. Rinaldo, W. J. Rhead, M. Kjeldsen, V. Winter, et al. 2001. Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr. Res. 49:18–23.
15. Crum, R. M., J. C. Anthony, S. S. Bassett, and M. F. Folstein. 1993. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269:2386– 2391.
16. Deelen, J., M. Beekman, H. W. Uh, Q. Helmer, M. Kuningas, L. Christiansen, et al. 2011. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 10:686–698.
17. Deng, H. X., W. Chen, S. T. Hong, K. M. Boycott, G. H. Gorrie, N. Siddique, et al. 2011. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:211–215.
18. Dorschner, M. O., L. M. Amendola, E. H. Turner, P. D. Robertson, B. H. Shirts, C. J. Gallego, et al. 2013. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am. J. Hum. Genet. 93:631–640.
19. Duzkale, H., J. Shen, H. McLaughlin, A. Alfares, M. Kelly, T. Pugh, et al. 2013. A systematic approach to assessing the clinical significance of genetic variants. Clin. Genet. 84:453– 463.
20. Flannick, J., N. L. Beer, A. G. Bick, V. Agarwala, J. Molnes, N. Gupta, et al. 2013. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat. Genet. 45:1380–1385.
21. Folstein, M. F., S. E. Folstein, and P. R. McHugh. 1975. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189–198.
22. Forcet, C., S. Etienne-Manneville, H. Gaude, L. Fournier, S. Debilly, and M. Salmi, et al. 2005. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum. Mol. Genet. 14:1283– 1292.
23. Genin, E., D. Hannequin, D. Wallon, K. Sleegers, M. Hiltunen, O. Combarros, et al. 2011. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 16:903–907.
24. Green, R. C., J. R. Lupski, and L. G. Biesecker. 2013a. Reporting genomic sequencing results to ordering clinicians: incidental, but not exceptional. JAMA 310:365–366.
25. Green, R. C., J. S. Berg, W. W. Grody, S. S. Kalia, B. R. Korf, C. L. Martin, et al. 2013b. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15:565–574.
26. Hamosh, A., A. F. Scott, J. S. Amberger, C. A. Bocchini, and V. A. McKusick. 2005. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33:D514–D517.
27. Haywood, A. F., N. D. Merner, K. A. Hodgkinson, J. Houston, P. Syrris, V. Booth, et al. 2013. Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. Eur. Heart J. 34:1002–1011.
28. Hindorff, L. A., P. Sethupathy, H. A. Junkins, E. M. Ramos, J. P. Mehta, F. S. Collins, et al. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106:9362–9367.
29. Johnston, J. J., W. S. Rubinstein, F. M. Facio, D. Ng, L. N. Singh, J. K. Teer, et al. 2012. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am. J. Hum. Genet. 91:97–108.
30. Jonsson, T., J. K. Atwal, S. Steinberg, J. Snaedal, P. V. Jonsson, S. Bjornsson, et al. 2012. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488:96–99.
31. Juul, K., A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard. 2004. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann. Intern. Med. 140:330–337.
32. Kenna, K. P., R. L. McLaughlin, O. Hardiman, and D. G. Bradley. 2013. Using reference databases of genetic variation to evaluate the potential pathogenicity of candidate disease variants. Hum. Mutat. 34:836–841.
33. Kent, W. J. 2002. BLAT–the BLAST-like alignment tool. Genome Res. 12:656–664.
34. Kieny, P., S. Chollet, P. Delalande, M. Le Fort, A. Magot, Y. Pereon, et al. 2013. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann. Phys. Rehabil. Med. 56:443–454.
35. Kingsmore, S. F.. 2013. Incidental swimming with millstones. Sci. Transl. Med. 5:194ed10.
36. Klitzman, R., P. S. Appelbaum, and W. Chung. 2013. Return of secondary genomic findings vs patient autonomy: implications for medical care. JAMA 310:369–370.
37. Landrum, M. J., J. M. Lee, G. R. Riley, W. Jang, W. S. Rubinstein, D. M. Church, et al. 2014. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42:D980–D985.
38. Lee, H., and M. C. Schatz. 2012. Genomic dark matter: the reliability of short read mapping illustrated by the genome mappability score. Bioinformatics 28:2097–2105.
39. Li, H., and R. Durbin. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760.
40. Lohn, Z., S. Adam, P. H. Birch, and J. M. Friedman. 2013. Incidental findings from clinical genome-wide sequencing: a review. J. Genet. Couns. doi: 10.1007/s10897-013-9604-4.
41. Lyon, G. J., and K. Wang. 2012. Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress. Genome Med. 4:58.
42. van Maldegem, B. T., M. Duran, R. J. Wanders, K. E. Niezen-Koning, M. Hogeveen, L. Ijlst, et al. 2006. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 296:943– 952.
43. Manolio, T. A., R. L. Chisholm, B. Ozenberger, D. M. Roden, M. S. Williams, R. Wilson, et al. 2013. Implementing genomic medicine in the clinic: the future is here. Genet. Med. 15:258–267.
44. Matsushita, Y., T. Furukawa, H. Kasanuki, M. Nishibatake, Y. Kurihara, A. Ikeda, et al. 2007. Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy. J. Hum. Genet. 52:543–548.
45. McKenna, A., M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, et al. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303.
46. Meyer, L. R., A. S. Zweig, A. S. Hinrichs, D. Karolchik, R. M. Kuhn, M. Wong, et al. 2012. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res. 41:D64–D69.
47. Miller, B. S., H. H. Freeze, G. F. Hoffmann, and K. Sarafoglou. 2011. Pubertal development in ALG6 deficiency (congenital disorder of glycosylation type Ic). Mol. Genet. Metab. 103:101–103.
48. Minoretti, P., C. Falcone, A. Aldeghi, V. Olivieri, F. Mori, E. Emanuele, et al. 2006. A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction. Clin. Chim. Acta 370:124–128.
49. Mohler, P. J., J. J. Schott, A. O. Gramolini, K. W. Dilly, S. Guatimosim, W. H. duBell, et al. 2003. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421:634–639.
50. Mohler, P. J., I. Splawski, C. Napolitano, G. Bottelli, L. Sharpe, K. Timothy, et al. 2004. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc. Natl. Acad. Sci. USA 101:9137–9142.
51. Nalls, M. A., R. Duran, G. Lopez, M. Kurzawa-Akanbi, I. G. McKeith, P. F. Chinnery, et al. 2013. A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies. JAMA Neurol. 70:727–735.
52. Nussbaum, R. L., R. R. McInnes, and H. F. H. Willard. 2007. Genetics in medicine. 7th ed. Pp. 122–126. Thompson & Thompson, Philadelphia, PA.
53. Pedersen, C. B., S. Kolvraa, A. Kolvraa, V. Stenbroen, M. Kjeldsen, R. Ensenauer, et al. 2008. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum. Genet. 124:43–56.
54. Poetter, K., H. Jiang, S. Hassanzadeh, S. R. Master, A. Chang, M. C. Dalakas, et al. 1996. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat. Genet. 13:63–69.
55. Rebbeck, T. R., A. H. Walker, C. Zeigler-Johnson, S. Weisburg, A. M. Martin, K. L. Nathanson, et al. 2000. Association of HPC2/ELAC2 genotypes and prostate cancer. Am. J. Hum. Genet. 67:1014–1019.
56. Rehm, H. L., S. J. Bale, P. Bayrak-Toydemir, J. S. Berg, K. K. Brown, J. L. Deignan, et al. 2013. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15:733–747.
57. Riggs, E. R., K. E. Wain, D. Riethmaier, M. Savage, B. Smith-Packard, E. B. Kaminsky, et al. 2013. Towards a Universal Clinical Genomics Database: the 2012 International Standards for Cytogenomic Arrays Consortium Meeting. Hum. Mutat. 34:915–919.
58. Schachter, F., L. Faure-Delanef, F. Guenot, H. Rouger, P. Froguel, L. Lesueur-Ginot, et al. 1994. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 6:29–32.
59. Scott, S. A., L. Edelmann, L. Liu, M. Luo, R. J. Desnick, and R. Kornreich. 2010. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum. Mutat. 31:1240–1250.
60. Sidransky, E., M. A. Nalls, J. O. Aasly, J. Aharon-Peretz, G. Annesi, E. R. Barbosa, et al. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 361:1651–1661.
61. Splawski, I., J. Shen, K. W. Timothy, M. H. Lehmann, S. Priori, J. L. Robinson, et al. 2000. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102:1178–1185.
62. Tavtigian, S. V., J. Simard, D. H. Teng, V. Abtin, M. Baumgard, A. Beck, et al. 2001. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27:172– 180.
63. Tein, I., O. Elpeleg, B. Ben-Zeev, S. H. Korman, A. Lossos, D. Lev, et al. 2008. Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. Mol. Genet. Metab. 93:179–189.
64. Temme, J., F. Peters, K. Lange, Y. Pirson, L. Heidet, R. Torra, et al. 2012. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 81:779–783.
65. Zhuang, S., A. Linhananta, and H. Li. 2010. Phenotypic effects of Ehlers-Danlos syndrome-associated mutation on the FnIII domain of tenascin-X. Protein Sci. 19:2231–2239.
66. Zweers, M. C., W. B. Dean, T. H. van Kuppevelt, J. Bristow, and J. Schalkwijk. 2005. Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations. Clin. Genet. 67:330–334.